Alnylam Pharmaceuticals and Regeneron Pharmaceuticals will collaborate to develop and commercialize new RNA interference therapies for ocular and central nervous system diseases, the companies announced in a press release.
Regeneron will lead development and commercialization for all eye disease programs, paying milestone and royalty payments to Alnylam under the terms of the agreement. The companies will work together and alternate leadership on CNS programs, the release said.
Regeneron will make an upfront payment of $400 million and purchase $400 million of Alnylam equity at $90 per share.
Uncategorized